Longevity
Sermorelin vs HGH: How the Two Actually Differ
Injected HGH is the hormone itself; sermorelin is a releasing peptide that signals the pituitary to secrete its own growth hormone, keeping the body's feedback brakes in the loop. That mechanistic difference drives everything people ask about: legality, price, safety logic, and why one is tightly controlled while the other lives in compounding, under rules the FDA tightened in January 2026.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 9 min read
Key facts
- HGH (somatropin) is recombinant growth hormone injected directly; sermorelin is a fragment of the natural releasing hormone that prompts the pituitary to secrete its own.
- Because sermorelin works through the pituitary, the body's negative-feedback loops remain in play, the core of its safety argument versus direct hormone.
- Federal law restricts HGH distribution to specific approved indications; anti-aging is not one. Sermorelin is not under that statute and is available as a compounded prescription.
- Sermorelin was once an FDA-approved product (Geref) for pediatric use; it was discontinued commercially, and current products are compounded, not FDA-approved.
- In January 2026, FDA guidance tightened compounded sermorelin access, requiring documented medical necessity relative to approved alternatives.
- Typical compounded pricing runs a few hundred dollars monthly, versus four figures for approved somatropin products.
What is the mechanistic difference, in plain terms?
Growth hormone therapy injects the finished hormone: levels rise because you put them there, regardless of what the body thinks about it. Sermorelin is a synthetic fragment of growth-hormone-releasing hormone, the signal the hypothalamus normally sends; injected, it asks the pituitary to secrete growth hormone itself, in its natural pulsatile pattern, and the body's feedback machinery, which suppresses release when levels are adequate, stays connected.
That intact feedback loop is the entire safety logic cited for the releasing-peptide approach: overshoot is self-limited in a way direct hormone administration is not. It is a genuinely different pharmacological philosophy, stimulate the gland versus replace its output, and it is why the two are regulated so differently.
Why is HGH so restricted while sermorelin is prescribable?
HGH sits under an unusual federal statute that limits its distribution to specific FDA-approved indications, documented deficiency states chief among them, and makes off-label anti-aging distribution a legal violation, not merely off-label practice. That is why legitimate adult HGH therapy requires formal deficiency workup, stimulation testing included, and why anti-aging HGH clinics operate on legally thin ice.
Sermorelin is a different molecule outside that statute. Its original approved product, Geref, was a pediatric medication discontinued commercially years ago; since then it has lived in pharmacy compounding as a patient-specific prescription, which made it the accessible sibling and, predictably, the heavily marketed one. Compounded sermorelin is not FDA-approved, and the evidence for the uses it is marketed for in adults, body composition, sleep, recovery, is thin, resting on the physiology and small studies rather than outcome trials.
What changed in January 2026?
FDA guidance took direct aim at the compounded peptide category, sermorelin included: prescriptions now require documented medical necessity, meaning the prescriber records why FDA-approved alternatives are inappropriate or inaccessible for that specific patient, and state boards moved to adopt the standard quickly. The practical effect is a higher evidentiary bar at the prescription step, and the disappearance of the casual subscription model where a questionnaire produced a peptide by mail.
For patients this is mostly protective: it forces the conversation that should have existed anyway, what specifically is this for, what was considered first, and how will anyone know if it is working. A platform operating properly under the 2026 rules will show you that documentation logic rather than routing around it.